1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Issue Size
45,00,000 shares (agg. up to ₹[.] Cr)
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 75.38 | 68.82 | 37.59 | 38.55 |
| Total Income | 71.87 | 79.94 | 56.72 | 44.51 |
| Profit After Tax | 5.63 | 7.36 | 4.14 | 0.87 |
| EBITDA | 9.19 | 11.80 | 7.01 | 3.27 |
| NET Worth | 15.62 | 9.99 | 2.63 | -1.50 |
| Reserves and Surplus | 15.32 | 9.69 | 2.33 | -1.80 |
| Total Borrowing | 21.05 | 18.75 | 18.37 | 18.48 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹154.90 |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹40.09 |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹167.95 |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹282.75 |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹281.70 |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹110.20 |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹273.95 |
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹66.41 |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹542.05 |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,119.40 |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,804.10 |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹172.29 |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹14.63 |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure towards construction of the proposed corporate office and guest house of the company in Tamil Nadu, India | 4.79 |
| 2 | Funding capital expenditure towards procurement of machineries for expansion and upgradation of the existing manufacturing facility in Puducherry, India | 7.45 |
| 3 | Repayment and/or pre-payment, in full or in part, of certain outstanding borrowings availed by the company | 13.50 |
| 4 | Funding incremental working capital requirements; and | 19.50 |
| 5 | General Corporate Purposes | |
| Total | 45.25 |
About Sai Primus Lifebiotech IPO
ncorporated in March 2017, Sai Primus Lifebiotech Limited is a pharmaceutical and nutraceutical Contract Development and Manufacturing Organization (CDMO) specializing in the manufacturing of oral solid dosage (OSD) formulations, including tablets and capsules. The company provides third-party contract manufacturing, private labelling, product development, regulatory support, and direct branding under its own "SPL" brand for domestic and international markets. The company manufactures a wide range of pharmaceutical products across therapeutic segments such as anti-diabetics, anti-hypertensives, anti-infectives, and analgesics, along with nutraceutical products focused on immunity, wellness, bone health, liver health, and general nutrition. Its operations include formulation development, raw material sourcing, manufacturing, packaging, quality control, documentation, and exports. The manufacturing facility in Puducherry is supported by in-house R&D, Quality Assurance (QA), and Quality Control (QC) laboratories and holds WHO-GMP, FSSAI, HACCP, and multiple international regulatory approvals. Since entering export markets in 2020, Sai Primus has expanded its portfolio to over 279 phar
Contact Details
Sai Primus Lifebiotech Ltd. AddressR.S.No.4/3, Plot No.33KurumbapetPuducherry, Puducherry, 6050090413 - 296631investors@splbiotech.comVisit Website